Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 21 min ago
Peer-reviewedCC BY-NC 4.0Therapeutic Apheresis and Dialysis

Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia

  • Yasutaka Yamauchi1,2
  • Rie Tanaka3
  • Reona Kawahira3
  • Shingo Nabeta3
  • Kouhei Naoi3,4
  • Kazuhito Kitajima3,4
  • Akira Wada3
  • Tomonari Takagi1,5
  • Norihiko Ohura1,6,7
  • Akira Miyamoto1,2,5
7 affiliations
  1. 1Cardiovascular Center, Takatsu General Hospital Kawasaki Kanagawa Japan
  2. 2Department of Cardiology Tokyo Heart Center, Osaki Hospital Tokyo Japan
  3. 3Department of Clinical Engineer Takatsu General Hospital Kawasaki Kanagawa Japan
  4. 4Department of Clinical Engineer Tokyo Heart Center, Osaki Hospital Tokyo Japan
  5. 5Department of Cardiology Tokyo Kamata Hospital Tokyo Japan
  6. 6Department of Plastic and Reconstructive Surgery Kyorin University Hospital Tokyo Japan
  7. 7Department of Plastic and Reconstructive Surgery Tokyo Heart Center, Osaki Hospital Tokyo Japan
Read full textDOICite

Abstract

Introduction: This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds.

Methods: Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment. Changes in mean low‐density lipoprotein cholesterol (LDL‐C), fibrinogen, C‐reactive protein (CRP), white blood cell (WBC) count, platelet count, blood flow, and wound improvement were compared between treatment initiation and completion.

Results: The treatment never required discontinuation due to in‐circuit coagulation or hypotension, and its safety was confirmed. After 10 treatment sessions, LDL‐C and fibrinogen removal rates were 24.3% and 24.4%, respectively. Platelet, WBC, and CRP values did not change significantly over time. Blood flow increased during treatment and posttreatment. All patients experienced wound improvement and favorable clinical outcomes.

Conclusion: Single‐needle Rheocarna therapy is effective for wound healing in CLTI. If this method applies to nondialysis patients without arteriovenous fistulas, indications for Rheocarna therapy will likely expand.

Related

  1. Anatomical Predictors of Endovascular Technical Success in Chronic Limb-Threatening Ischemia: The Role of GLASS and Diabetes
    Anca Dumitrescu-Bordianu, Livia Genoveva Baroi, Radu Florin Popa +10
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Orthoplastic Limb Salvage Using Transtibial Transport and Free-Flap Reconstruction in Patients With Diabetes-Related Chronic Limb-Threatening Ischemia
    Johnson Boey, Jingjing Wen, Zhegang Zhou
    Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMCEurope PMC
  3. C-reactive Protein-to-Albumin Ratio for Evaluating Patients with Chronic Limb-Threatening Ischemia Following Endovascular Therapy
    Akinori Satake, Takahiro Tokuda, Hiroaki Sawada +8
    Journal of Atherosclerosis and ThrombosisPeer-reviewedCC BY-NC-SAFull textSurgery & anaesthesiaJ-STAGE
  4. Liver Dysfunction Assessed by Albumin – Bilirubin (ALBI) Score is Associated with Disturbed Cholesterol Profiles and Reduced Survival in Patients with Chronic Limb-Threatening Ischemia
    Kentaro Inoue, Shinichiro Yoshino, Yutaka Matsubara +2
    Journal of Atherosclerosis and ThrombosisPeer-reviewedCC BY-NC-SAFull textSurgery & anaesthesiaJ-STAGE
  5. Bilateral Lateral Tarsal Artery Bypass and Free Flap Reconstruction of an Infected Gangrenous Heel in Chronic Limb-Threatening Ischemia: A Case Report of Three-Year Functional Limb Salvage
    Noriyuki Yokoyama, Shinsuke Kikuchi, Hirofumi Jinno +9
    Surgical Case ReportsPeer-reviewedCC BY 4.0Full textSurgery & anaesthesiaPMC

Cite

BibTeXRIS
BibTeX
@article{yamauchi2026experience,
  title = {{Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia}},
  author = {Yasutaka Yamauchi and Rie Tanaka and Reona Kawahira and Shingo Nabeta and Kouhei Naoi and Kazuhito Kitajima and Akira Wada and Tomonari Takagi and Norihiko Ohura and Akira Miyamoto},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  month = jun,
  doi = {10.1002/1744-9987.70161},
  url = {https://doi.org/10.1002/1744-9987.70161},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia
AU  - Yasutaka Yamauchi
AU  - Rie Tanaka
AU  - Reona Kawahira
AU  - Shingo Nabeta
AU  - Kouhei Naoi
AU  - Kazuhito Kitajima
AU  - Akira Wada
AU  - Tomonari Takagi
AU  - Norihiko Ohura
AU  - Akira Miyamoto
PY  - 2026
DA  - 2026/06/09
JO  - Therapeutic Apheresis and Dialysis
DO  - 10.1002/1744-9987.70161
UR  - https://doi.org/10.1002/1744-9987.70161
AB  - Introduction: This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds.  Methods: Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment. Changes in mean low‐density lipoprotein cholesterol (LDL‐C), fibrinogen, C‐reactive protein (CRP), white blood cell (WBC) count, platelet count, blood flow, and wound improvement were compared between treatment initiation and completion.  Results: The treatment never required discontinuation due to in‐circuit coagulation or hypotension, and its safety was confirmed. After 10 treatment sessions, LDL‐C and fibrinogen removal rates were 24.3% and 24.4%, respectively. Platelet, WBC, and CRP values did not change significantly over time. Blood flow increased during treatment and posttreatment. All patients experienced wound improvement and favorable clinical outcomes.  Conclusion: Single‐needle Rheocarna therapy is effective for wound healing in CLTI. If this method applies to nondialysis patients without arteriovenous fistulas, indications for Rheocarna therapy will likely expand.
SN  - 1744-9979
SN  - 1744-9987
ER  -